Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. boosted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 25.1% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 5,290 shares of the pharmaceutical company’s stock after buying an additional 1,061 shares during the period. E Fund Management Co. Ltd.’s holdings in Vertex Pharmaceuticals were worth $2,480,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in VRTX. Groesbeck Investment Management Corp NJ lifted its stake in shares of Vertex Pharmaceuticals by 1.2% in the 2nd quarter. Groesbeck Investment Management Corp NJ now owns 1,794 shares of the pharmaceutical company’s stock valued at $841,000 after purchasing an additional 21 shares in the last quarter. Institute for Wealth Management LLC. lifted its stake in shares of Vertex Pharmaceuticals by 0.6% in the 2nd quarter. Institute for Wealth Management LLC. now owns 3,586 shares of the pharmaceutical company’s stock valued at $1,681,000 after purchasing an additional 22 shares in the last quarter. Drive Wealth Management LLC lifted its stake in shares of Vertex Pharmaceuticals by 2.0% in the 2nd quarter. Drive Wealth Management LLC now owns 1,101 shares of the pharmaceutical company’s stock valued at $516,000 after purchasing an additional 22 shares in the last quarter. RFP Financial Group LLC lifted its stake in shares of Vertex Pharmaceuticals by 17.0% in the 2nd quarter. RFP Financial Group LLC now owns 158 shares of the pharmaceutical company’s stock valued at $74,000 after purchasing an additional 23 shares in the last quarter. Finally, Hohimer Wealth Management LLC lifted its stake in shares of Vertex Pharmaceuticals by 0.8% in the 4th quarter. Hohimer Wealth Management LLC now owns 2,932 shares of the pharmaceutical company’s stock valued at $1,193,000 after purchasing an additional 24 shares in the last quarter. 90.96% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Vertex Pharmaceuticals news, CMO Carmen Bozic sold 2,280 shares of the business’s stock in a transaction on Wednesday, June 26th. The stock was sold at an average price of $471.72, for a total transaction of $1,075,521.60. Following the completion of the transaction, the chief marketing officer now owns 30,099 shares in the company, valued at approximately $14,198,300.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Vertex Pharmaceuticals news, Chairman Jeffrey M. Leiden sold 3,784 shares of the business’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $499.00, for a total transaction of $1,888,216.00. Following the completion of the transaction, the chairman now owns 9,994 shares in the company, valued at approximately $4,987,006. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CMO Carmen Bozic sold 2,280 shares of the business’s stock in a transaction on Wednesday, June 26th. The stock was sold at an average price of $471.72, for a total value of $1,075,521.60. Following the transaction, the chief marketing officer now owns 30,099 shares of the company’s stock, valued at approximately $14,198,300.28. The disclosure for this sale can be found here. In the last quarter, insiders sold 34,047 shares of company stock worth $16,843,806. 0.20% of the stock is owned by company insiders.

Vertex Pharmaceuticals Trading Down 1.7 %

NASDAQ:VRTX opened at $481.26 on Wednesday. Vertex Pharmaceuticals Incorporated has a 12-month low of $341.85 and a 12-month high of $510.64. The firm has a market capitalization of $124.19 billion, a P/E ratio of 31.23 and a beta of 0.40. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.52 and a quick ratio of 2.26. The business has a 50 day simple moving average of $483.77 and a 200 day simple moving average of $451.24.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Thursday, August 1st. The pharmaceutical company reported ($12.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($12.54) by ($0.29). Vertex Pharmaceuticals had a negative net margin of 4.74% and a negative return on equity of 2.45%. The company had revenue of $2.65 billion for the quarter, compared to analyst estimates of $2.66 billion. During the same quarter in the prior year, the firm earned $3.53 EPS. The company’s revenue for the quarter was up 6.1% compared to the same quarter last year. Equities research analysts predict that Vertex Pharmaceuticals Incorporated will post -2.14 EPS for the current year.

Analyst Ratings Changes

VRTX has been the topic of several research analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Friday, July 26th. Morgan Stanley raised their target price on Vertex Pharmaceuticals from $402.00 to $455.00 and gave the company an “equal weight” rating in a report on Thursday, July 11th. Oppenheimer raised their target price on Vertex Pharmaceuticals from $500.00 to $550.00 and gave the company an “outperform” rating in a report on Monday, August 5th. TD Cowen raised their target price on Vertex Pharmaceuticals from $450.00 to $500.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Finally, StockNews.com downgraded Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, August 5th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Vertex Pharmaceuticals currently has an average rating of “Hold” and an average price target of $485.91.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.